These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1619397)

  • 1. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys.
    McCormick JB; Mitchell SW; Kiley MP; Ruo S; Fisher-Hoch SP
    J Med Virol; 1992 May; 37(1):1-7. PubMed ID: 1619397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.
    Fisher-Hoch SP; McCormick JB; Auperin D; Brown BG; Castor M; Perez G; Ruo S; Conaty A; Brammer L; Bauer S
    Proc Natl Acad Sci U S A; 1989 Jan; 86(1):317-21. PubMed ID: 2911575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
    Zapata JC; Poonia B; Bryant J; Davis H; Ateh E; George L; Crasta O; Zhang Y; Slezak T; Jaing C; Pauza CD; Goicochea M; Moshkoff D; Lukashevich IS; Salvato MS
    Virol J; 2013 Feb; 10():52. PubMed ID: 23402317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP; McCormick JB
    Rev Med Virol; 2001; 11(5):331-41. PubMed ID: 11590670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay.
    Niklasson BS; Jahrling PB; Peters CJ
    J Clin Microbiol; 1984 Aug; 20(2):239-44. PubMed ID: 6386846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus.
    Walker DH; Johnson KM; Lange JV; Gardner JJ; Kiley MP; McCormick JB
    J Infect Dis; 1982 Sep; 146(3):360-8. PubMed ID: 6286795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.
    Jahrling PB; Peters CJ
    Infect Immun; 1984 May; 44(2):528-33. PubMed ID: 6715049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys.
    Lange JV; Mitchell SW; McCormick JB; Walker DH; Evatt BL; Ramsey RR
    Am J Trop Med Hyg; 1985 Sep; 34(5):999-1007. PubMed ID: 4037187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever.
    Fisher-Hoch SP; Mitchell SW; Sasso DR; Lange JV; Ramsey R; McCormick JB
    J Infect Dis; 1987 Mar; 155(3):465-74. PubMed ID: 3543155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.
    ter Meulen J; Badusche M; Kuhnt K; Doetze A; Satoguina J; Marti T; Loeliger C; Koulemou K; Koivogui L; Schmitz H; Fleischer B; Hoerauf A
    J Virol; 2000 Mar; 74(5):2186-92. PubMed ID: 10666248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys.
    Mateo M; Reynard S; Pietrosemoli N; Perthame E; Journeaux A; Noy K; Germain C; Carnec X; Picard C; Borges-Cardoso V; Hortion J; Lopez-Maestre H; Regnard P; Fellmann L; Vallve A; Barron S; Jourjon O; Lacroix O; Duthey A; Dirheimer M; Daniau M; Legras-Lachuer C; Carbonnelle C; Raoul H; Tangy F; Baize S
    Nat Commun; 2023 Mar; 14(1):1352. PubMed ID: 36906645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An evaluation of the possibility of obtaining an inactivated vaccine against Lassa fever].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):74-5. PubMed ID: 7879553
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
    Zapata JC; Goicochea M; Nadai Y; Eyzaguirre LM; Carr JK; Tallon LJ; Sadzewicz L; Myers G; Fraser CM; Su Q; Djavani M; Lukashevich IS; Salvato MS
    J Virol; 2014 Mar; 88(6):3058-66. PubMed ID: 24335292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.